Gene symbol |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
14927508 3 |  |
149275083 |
Unknown |
KLA | .74 |
.68 |
.68 |
.77 |
.71 |
.85 |
.69 |
| ATP | .85 |
.69 |
1.26 |
.89 |
.89 |
1.26 |
.64 |
| KLA/ATP | .64 |
.63 |
1.07 |
.96 |
1.39 |
1.07 |
.82 |
|
Abl1 |  |
AK083248 |
adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630031E05 product:v-abl Abelson murine leukemia oncogene 1, full insert sequence. [AK083248] |
KLA | 1.07 |
1.07 |
.92 |
1.01 |
.98 |
1.07 |
.98 |
| ATP | .98 |
.99 |
.94 |
.90 |
.99 |
1.07 |
1.04 |
| KLA/ATP | 1.04 |
1.01 |
1.03 |
.98 |
.97 |
.95 |
.99 |
|
Abl1 |  |
NM_009594 |
c-abl oncogene 1, receptor tyrosine kinase (Abl1), transcript variant 2, mRNA [NM_009594] |
KLA | .63 |
.62 |
.65 |
.71 |
.96 |
1.17 |
1.05 |
| ATP | 1.01 |
1.16 |
1.03 |
1.14 |
1.12 |
.98 |
.98 |
| KLA/ATP | .66 |
.64 |
.67 |
.73 |
.84 |
.90 |
1.05 |
|
Abl2 |  |
NM_009595 |
v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene) (Abl2), mRNA [NM_009595] |
KLA | 1.26 |
1.26 |
1.10 |
1.05 |
.90 |
1.02 |
1.10 |
| ATP | 1.01 |
1.21 |
2.17 |
2.69 |
2.85 |
1.53 |
1.35 |
| KLA/ATP | 1.23 |
1.31 |
1.44 |
1.47 |
2.45 |
1.54 |
1.39 |
|
Actb |  |
BC016624 |
cDNA clone IMAGE:4501052 [BC016624] |
KLA | 1.20 |
1.20 |
1.19 |
1.73 |
1.83 |
2.52 |
1.70 |
| ATP | 1.04 |
1.01 |
1.03 |
.92 |
1.07 |
.66 |
.91 |
| KLA/ATP | 1.34 |
1.40 |
1.69 |
1.28 |
1.27 |
1.19 |
1.06 |
|
Actb |  |
NM_007393 |
actin, beta, cytoplasmic (Actb), mRNA [NM_007393] |
KLA | 1.58 |
1.64 |
1.59 |
2.02 |
2.03 |
3.04 |
1.75 |
| ATP | 1.00 |
.95 |
1.26 |
1.18 |
1.33 |
.86 |
.91 |
| KLA/ATP | 1.52 |
1.75 |
2.42 |
1.92 |
2.17 |
1.54 |
1.28 |
|
Actg1 |  |
NM_009609 |
actin, gamma, cytoplasmic 1 (Actg1), mRNA [NM_009609] |
KLA | 1.02 |
1.03 |
1.34 |
1.07 |
1.49 |
1.58 |
.71 |
| ATP | 1.07 |
1.24 |
.76 |
.76 |
.63 |
.46 |
.78 |
| KLA/ATP | 1.20 |
1.30 |
.75 |
.82 |
.60 |
.53 |
.55 |
|
Bid |  |
NM_007544 |
BH3 interacting domain death agonist (Bid), mRNA [NM_007544] |
KLA | 1.03 |
1.08 |
1.09 |
1.14 |
1.01 |
.99 |
.68 |
| ATP | 1.06 |
1.11 |
.97 |
.89 |
1.04 |
1.17 |
1.08 |
| KLA/ATP | .88 |
1.09 |
.92 |
1.06 |
1.16 |
1.28 |
1.56 |
|
Casp3 |  |
NM_009810 |
caspase 3 (Casp3), mRNA [NM_009810] |
KLA | 1.66 |
1.94 |
2.47 |
2.61 |
3.01 |
2.96 |
1.44 |
| ATP | .90 |
.99 |
1.17 |
1.30 |
1.01 |
1.17 |
.86 |
| KLA/ATP | 1.55 |
1.87 |
2.40 |
2.35 |
2.27 |
2.84 |
2.52 |
|
Casp3 |  |
U49929 |
ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] |
KLA | 1.71 |
1.87 |
2.69 |
3.11 |
3.64 |
3.42 |
1.52 |
| ATP | 1.04 |
1.07 |
1.16 |
1.34 |
.98 |
1.27 |
.86 |
| KLA/ATP | 1.80 |
1.96 |
2.46 |
2.91 |
2.50 |
3.24 |
3.10 |
|
Casp8 |  |
NM_009812 |
caspase 8 (Casp8), transcript variant 1, mRNA [NM_009812] |
KLA | 2.41 |
2.53 |
3.20 |
3.26 |
2.75 |
2.78 |
1.57 |
| ATP | .91 |
.96 |
.66 |
.67 |
.54 |
1.53 |
1.52 |
| KLA/ATP | 2.47 |
2.52 |
2.08 |
2.41 |
1.41 |
2.50 |
2.77 |
|
Casp9 |  |
NM_015733 |
caspase 9 (Casp9), mRNA [NM_015733] |
KLA | .31 |
.31 |
.40 |
.66 |
.89 |
1.19 |
.91 |
| ATP | .88 |
.77 |
.91 |
.59 |
.43 |
.75 |
.93 |
| KLA/ATP | .26 |
.26 |
.30 |
.28 |
.80 |
1.06 |
.97 |
|
Cav1 |  |
NM_007616 |
caveolin, caveolae protein 1 (Cav1), mRNA [NM_007616] |
KLA | 14.41 |
13.85 |
11.14 |
10.72 |
9.47 |
4.26 |
1.52 |
| ATP | 1.05 |
1.13 |
1.37 |
1.72 |
3.27 |
15.82 |
13.01 |
| KLA/ATP | 12.62 |
15.59 |
16.15 |
16.68 |
11.37 |
8.19 |
14.27 |
|
Ccnd1 |  |
S78355 |
gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] |
KLA | .24 |
.23 |
.23 |
.24 |
.29 |
.47 |
.17 |
| ATP | 1.02 |
1.02 |
.88 |
.80 |
.52 |
.10 |
.21 |
| KLA/ATP | .27 |
.23 |
.22 |
.24 |
.27 |
.25 |
.14 |
|
Cd28 |  |
NM_007642 |
CD28 antigen (Cd28), mRNA [NM_007642] |
KLA | .52 |
.51 |
.45 |
.50 |
.36 |
.33 |
.18 |
| ATP | 1.11 |
1.26 |
1.08 |
1.25 |
1.99 |
1.42 |
2.08 |
| KLA/ATP | .51 |
.51 |
.58 |
.60 |
.56 |
.53 |
.38 |
|
Cd40 |  |
NM_170701 |
CD40 antigen (Cd40), transcript variant 3, mRNA [NM_170701] |
KLA | 23.87 |
23.62 |
23.26 |
23.98 |
22.07 |
17.37 |
5.34 |
| ATP | 1.00 |
1.01 |
1.06 |
2.96 |
2.65 |
3.03 |
1.70 |
| KLA/ATP | 22.77 |
23.79 |
29.67 |
28.85 |
28.08 |
21.62 |
13.02 |
|
Cd40lg |  |
NM_011616 |
CD40 ligand (Cd40lg), mRNA [NM_011616] |
KLA | 1.03 |
1.07 |
1.02 |
.98 |
1.06 |
1.06 |
1.03 |
| ATP | .95 |
.92 |
.99 |
1.06 |
1.02 |
1.04 |
1.07 |
| KLA/ATP | 1.00 |
1.01 |
.93 |
1.04 |
.94 |
1.01 |
.98 |
|
Cd55 |  |
AF143541 |
decay accelerating factor glycosylphoshatidylinositol-anchored form (DAF) mRNA, partial cds. [AF143541] |
KLA | .98 |
1.01 |
1.05 |
1.08 |
.98 |
.99 |
1.03 |
| ATP | 1.01 |
1.00 |
.95 |
.96 |
1.04 |
1.06 |
1.00 |
| KLA/ATP | 1.01 |
.99 |
1.05 |
.97 |
1.03 |
.97 |
.96 |
|
Cd55 |  |
AK030285 |
11 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:5031405O06 product:decay accelerating factor 1, full insert sequence [AK030285] |
KLA | 1.28 |
1.22 |
1.35 |
1.29 |
1.26 |
1.42 |
2.37 |
| ATP | 1.02 |
.96 |
1.02 |
1.00 |
.92 |
.98 |
1.32 |
| KLA/ATP | 1.30 |
1.22 |
1.19 |
1.04 |
.96 |
1.02 |
1.33 |
|
Cd55 |  |
NM_010016 |
CD55 antigen (Cd55), mRNA [NM_010016] |
KLA | 1.81 |
1.70 |
1.81 |
1.92 |
2.16 |
2.13 |
4.63 |
| ATP | 1.09 |
1.04 |
1.16 |
1.05 |
1.14 |
1.32 |
1.92 |
| KLA/ATP | 1.80 |
1.89 |
1.79 |
1.56 |
1.26 |
1.39 |
3.24 |
|
Cd80 |  |
NM_009855 |
CD80 antigen (Cd80), mRNA [NM_009855] |
KLA | 2.13 |
1.91 |
1.89 |
1.78 |
1.29 |
1.00 |
.82 |
| ATP | .99 |
1.20 |
1.98 |
1.49 |
1.37 |
2.40 |
1.71 |
| KLA/ATP | 2.05 |
2.32 |
3.09 |
2.27 |
1.95 |
2.89 |
3.07 |
|
Cd86 |  |
NM_019388 |
CD86 antigen (Cd86), mRNA [NM_019388] |
KLA | 13.80 |
14.41 |
18.21 |
18.33 |
17.37 |
17.26 |
4.82 |
| ATP | 1.02 |
1.00 |
2.20 |
3.64 |
5.16 |
6.79 |
3.81 |
| KLA/ATP | 14.80 |
14.66 |
18.10 |
18.96 |
19.38 |
20.42 |
14.21 |
|
Cxadr |  |
NM_001025192 |
coxsackievirus and adenovirus receptor (Cxadr), transcript variant 1, mRNA [NM_001025192] |
KLA | .94 |
1.00 |
1.07 |
.96 |
1.02 |
1.08 |
1.01 |
| ATP | .92 |
.96 |
1.00 |
1.05 |
.98 |
.98 |
.93 |
| KLA/ATP | .92 |
1.00 |
1.00 |
1.03 |
.99 |
1.01 |
1.04 |
|
Cxadr |  |
NM_009988 |
coxsackievirus and adenovirus receptor (Cxadr), transcript variant 2, mRNA [NM_009988] |
KLA | 1.05 |
1.01 |
1.00 |
1.01 |
.97 |
.99 |
.94 |
| ATP | 1.03 |
1.00 |
1.00 |
.99 |
.99 |
1.04 |
1.02 |
| KLA/ATP | 1.01 |
1.02 |
1.02 |
.99 |
1.02 |
1.01 |
1.07 |
|
Cycs |  |
NM_007808 |
cytochrome c, somatic (Cycs), nuclear gene encoding mitochondrial protein, mRNA [NM_007808] |
KLA | 2.20 |
2.21 |
2.35 |
2.69 |
2.62 |
3.22 |
2.14 |
| ATP | .87 |
.89 |
1.31 |
1.05 |
1.06 |
1.20 |
1.26 |
| KLA/ATP | 1.88 |
2.04 |
2.86 |
2.26 |
2.57 |
2.45 |
2.03 |
|
Cyct |  |
NM_009989 |
cytochrome c, testis (Cyct), mRNA [NM_009989] |
KLA | .93 |
1.01 |
1.00 |
.99 |
1.02 |
1.03 |
.96 |
| ATP | 1.01 |
.91 |
1.01 |
.99 |
.98 |
.95 |
.95 |
| KLA/ATP | 1.10 |
.96 |
.89 |
.89 |
1.10 |
1.05 |
.97 |
|
Daf2 |  |
AK019553 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4921540H11 product:decay accelerating factor 2, full insert sequence. [AK019553] |
KLA | 1.04 |
.91 |
.97 |
.98 |
1.02 |
1.02 |
.95 |
| ATP | .97 |
1.03 |
.91 |
.96 |
.95 |
1.05 |
1.05 |
| KLA/ATP | .94 |
.99 |
1.00 |
1.00 |
.99 |
.97 |
1.02 |
|
Daf2 |  |
NM_007827 |
decay accelerating factor 2 (Daf2), mRNA [NM_007827] |
KLA | 1.06 |
.99 |
1.00 |
1.00 |
1.03 |
1.04 |
1.18 |
| ATP | 1.03 |
1.03 |
.93 |
1.05 |
.97 |
.85 |
.98 |
| KLA/ATP | 1.11 |
1.13 |
1.10 |
1.00 |
.93 |
1.05 |
1.02 |
|
Dag1 |  |
NM_010017 |
dystroglycan 1 (Dag1), mRNA [NM_010017] |
KLA | .74 |
.75 |
.67 |
.59 |
.62 |
.61 |
.66 |
| ATP | 1.16 |
1.24 |
.87 |
1.18 |
1.00 |
.91 |
1.17 |
| KLA/ATP | .88 |
.84 |
.53 |
.70 |
.75 |
.96 |
.90 |
|
Dmd |  |
AK044536 |
adult retina cDNA, RIKEN full-length enriched library, clone:A930019F21 product:DYSTROPHIN homolog [Mus musculus], full insert sequence. [AK044536] |
KLA | 1.02 |
.99 |
.98 |
1.00 |
.94 |
1.06 |
1.02 |
| ATP | .94 |
1.06 |
.95 |
.96 |
1.00 |
1.00 |
1.02 |
| KLA/ATP | .98 |
1.07 |
1.01 |
.86 |
.96 |
1.02 |
1.04 |
|
Dmd |  |
NM_007868 |
dystrophin, muscular dystrophy (Dmd), mRNA [NM_007868] |
KLA | 1.00 |
.99 |
1.00 |
1.02 |
1.02 |
1.00 |
1.03 |
| ATP | .99 |
1.03 |
1.02 |
1.03 |
1.00 |
1.01 |
1.00 |
| KLA/ATP | 1.03 |
1.03 |
1.01 |
1.01 |
1.03 |
1.04 |
.99 |
|
EG629860
|  |
M17953 |
gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] |
KLA | .96 |
1.05 |
1.03 |
1.08 |
1.08 |
1.02 |
.98 |
| ATP | .97 |
.99 |
1.05 |
1.10 |
.95 |
.94 |
.91 |
| KLA/ATP | .96 |
.94 |
.97 |
1.04 |
.97 |
1.01 |
.89 |
|
Eif4g1 |  |
NM_145941 |
eukaryotic translation initiation factor 4, gamma 1 (Eif4g1), transcript variant 1, mRNA [NM_145941] |
KLA | 1.14 |
1.11 |
1.21 |
1.05 |
1.01 |
.97 |
1.13 |
| ATP | 1.05 |
1.13 |
1.02 |
.94 |
.91 |
.96 |
1.08 |
| KLA/ATP | 1.17 |
1.21 |
1.03 |
.95 |
.77 |
.80 |
.88 |
|
Eif4g2 |  |
NM_001040131 |
eukaryotic translation initiation factor 4, gamma 2 (Eif4g2), transcript variant 2, mRNA [NM_001040131] |
KLA | 2.40 |
2.29 |
2.62 |
2.64 |
2.99 |
2.58 |
1.98 |
| ATP | 1.11 |
1.29 |
1.03 |
1.17 |
1.22 |
1.42 |
.90 |
| KLA/ATP | 2.25 |
2.47 |
1.96 |
2.07 |
1.24 |
1.34 |
1.14 |
|
Eif4g2 |  |
NM_013507 |
eukaryotic translation initiation factor 4, gamma 2 (Eif4g2), transcript variant 1, mRNA [NM_013507] |
KLA | 1.75 |
1.82 |
2.01 |
1.93 |
2.28 |
1.80 |
1.75 |
| ATP | 1.15 |
1.25 |
.94 |
1.03 |
1.03 |
1.03 |
.73 |
| KLA/ATP | 1.86 |
1.97 |
1.17 |
1.35 |
.91 |
.95 |
.95 |
|
Eif4g3 |  |
NM_172703 |
eukaryotic translation initiation factor 4 gamma, 3 (Eif4g3), mRNA [NM_172703] |
KLA | 1.22 |
1.10 |
1.42 |
1.45 |
1.56 |
1.21 |
1.06 |
| ATP | 1.14 |
1.11 |
1.06 |
.99 |
.82 |
.81 |
.91 |
| KLA/ATP | 1.25 |
1.21 |
1.57 |
1.30 |
.87 |
.72 |
1.15 |
|
Fyn |  |
U70324 |
Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] |
KLA | 1.23 |
1.27 |
1.31 |
1.27 |
1.31 |
.87 |
.48 |
| ATP | .88 |
.71 |
.66 |
.75 |
.90 |
1.28 |
.51 |
| KLA/ATP | 1.12 |
1.01 |
.94 |
.84 |
1.25 |
1.51 |
.53 |
|
H2-Aa |  |
NM_010378 |
histocompatibility 2, class II antigen A, alpha (H2-Aa), mRNA [NM_010378] |
KLA | 1.43 |
1.59 |
1.68 |
1.50 |
1.62 |
1.89 |
1.64 |
| ATP | 1.07 |
1.15 |
1.27 |
1.90 |
1.92 |
1.77 |
1.55 |
| KLA/ATP | 1.62 |
1.81 |
1.74 |
2.29 |
1.89 |
1.92 |
2.19 |
|
H2-Ab1 |  |
BC010322 |
histocompatibility 2, class II antigen A, beta 1, mRNA (cDNA clone MGC:6297 IMAGE:2651058), complete cds [BC010322] |
KLA | 1.73 |
1.76 |
1.77 |
1.55 |
1.95 |
2.10 |
2.27 |
| ATP | 1.03 |
1.18 |
1.32 |
1.99 |
1.79 |
1.56 |
1.61 |
| KLA/ATP | 1.70 |
2.01 |
1.74 |
2.52 |
1.58 |
2.01 |
2.75 |
|
H2-Ab1 |  |
NM_207105 |
histocompatibility 2, class II antigen A, beta 1 (H2-Ab1), mRNA [NM_207105] |
KLA | 2.02 |
2.15 |
2.07 |
2.09 |
2.32 |
2.78 |
3.08 |
| ATP | 1.11 |
1.20 |
1.42 |
2.33 |
2.33 |
2.25 |
1.87 |
| KLA/ATP | 2.11 |
2.32 |
2.52 |
3.62 |
2.67 |
2.96 |
5.04 |
|
H2-Bl |  |
NM_008199 |
histocompatibility 2, blastocyst (H2-Bl), mRNA [NM_008199] |
KLA | 1.29 |
1.32 |
1.40 |
1.28 |
1.36 |
1.46 |
1.80 |
| ATP | 1.04 |
1.11 |
1.02 |
1.34 |
1.28 |
1.32 |
1.47 |
| KLA/ATP | 1.32 |
1.39 |
1.34 |
1.77 |
1.41 |
1.61 |
2.39 |
|
H2-D1 |  |
AK169750 |
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430019E13 product:histocompatibility 2, D region locus 1, full insert sequence [AK169750] |
KLA | .99 |
.98 |
.96 |
.99 |
.93 |
.91 |
.94 |
| ATP | .96 |
1.01 |
1.02 |
.95 |
1.05 |
1.00 |
.98 |
| KLA/ATP | .92 |
.94 |
.97 |
.97 |
.98 |
.92 |
1.03 |
|
H2-D1 |  |
NM_010380 |
histocompatibility 2, D region locus 1 (H2-D1), mRNA [NM_010380] |
KLA | 1.38 |
1.45 |
1.73 |
1.42 |
1.70 |
1.76 |
2.56 |
| ATP | 1.15 |
1.11 |
.86 |
1.12 |
1.19 |
1.28 |
1.90 |
| KLA/ATP | 1.58 |
1.72 |
1.38 |
1.56 |
1.38 |
1.69 |
3.21 |
|
H2-DMa |  |
NM_010386 |
histocompatibility 2, class II, locus DMa (H2-DMa), mRNA [NM_010386] |
KLA | 1.49 |
1.50 |
1.65 |
1.65 |
1.91 |
2.23 |
1.69 |
| ATP | 1.04 |
1.12 |
1.26 |
1.67 |
1.24 |
.99 |
1.32 |
| KLA/ATP | 1.58 |
1.68 |
1.70 |
2.02 |
1.37 |
1.35 |
1.90 |
|
H2-DMb1 |  |
NM_010387 |
histocompatibility 2, class II, locus Mb1 (H2-DMb1), mRNA [NM_010387] |
KLA | 1.06 |
1.14 |
1.08 |
1.13 |
1.24 |
1.41 |
1.37 |
| ATP | 1.01 |
1.02 |
1.09 |
1.14 |
.92 |
.73 |
1.36 |
| KLA/ATP | 1.13 |
1.05 |
1.21 |
1.17 |
.98 |
.83 |
1.41 |
|
H2-DMb2 |  |
NM_010388 |
histocompatibility 2, class II, locus Mb2 (H2-DMb2), mRNA [NM_010388] |
KLA | 1.00 |
1.04 |
.93 |
.95 |
.96 |
.95 |
1.03 |
| ATP | 1.06 |
1.04 |
.94 |
.92 |
.97 |
.95 |
1.00 |
| KLA/ATP | .90 |
.94 |
.99 |
.94 |
.90 |
.96 |
.92 |
|
H2-Eb1 |  |
X52641 |
gb|Mouse mRNA for I-A beta NOD. [X52641] |
KLA | 1.94 |
2.06 |
1.94 |
1.87 |
1.96 |
2.18 |
1.76 |
| ATP | 1.11 |
1.20 |
1.53 |
2.70 |
3.02 |
2.91 |
1.40 |
| KLA/ATP | 2.09 |
2.11 |
2.26 |
3.55 |
2.76 |
3.05 |
3.05 |
|
H2-K1 |  |
M69070 |
mRNA, complete cds. [M69070] |
KLA | 1.76 |
1.66 |
1.78 |
1.78 |
1.87 |
2.23 |
2.99 |
| ATP | .98 |
.97 |
1.19 |
1.45 |
1.36 |
1.68 |
2.17 |
| KLA/ATP | 1.68 |
1.70 |
1.87 |
1.96 |
1.87 |
2.13 |
3.82 |
|
H2-K1 |  |
NM_001001892 |
histocompatibility 2, K1, K region (H2-K1), transcript variant 1, mRNA [NM_001001892] |
KLA | 1.82 |
1.66 |
1.73 |
1.76 |
1.87 |
2.29 |
3.17 |
| ATP | .98 |
.97 |
1.13 |
1.32 |
1.29 |
1.57 |
2.09 |
| KLA/ATP | 1.64 |
1.71 |
1.77 |
1.82 |
1.71 |
2.12 |
3.91 |
|
H2-M1 |  |
NM_177636 |
histocompatibility 2, M region locus 1 (H2-M1), mRNA [NM_177636] |
KLA | .99 |
1.01 |
1.02 |
1.02 |
.97 |
1.03 |
1.04 |
| ATP | 1.01 |
.99 |
1.03 |
1.07 |
.92 |
1.03 |
.98 |
| KLA/ATP | 1.08 |
.97 |
.94 |
1.04 |
1.00 |
1.04 |
1.02 |
|
H2-M10.1
|  |
NM_013544 |
histocompatibility 2, M region locus 10.1 (H2-M10.1), mRNA [NM_013544] |
KLA | 1.04 |
1.00 |
1.05 |
.95 |
.98 |
1.04 |
.94 |
| ATP | 1.06 |
1.04 |
.96 |
.95 |
.97 |
.98 |
.98 |
| KLA/ATP | 1.02 |
1.07 |
.98 |
1.02 |
.92 |
.92 |
.99 |
|
H2-M10.2
|  |
NM_177923 |
histocompatibility 2, M region locus 10.2 (H2-M10.2), mRNA [NM_177923] |
KLA | 2.18 |
2.23 |
2.51 |
2.61 |
2.90 |
3.30 |
3.40 |
| ATP | 1.08 |
1.02 |
1.22 |
1.39 |
1.30 |
1.56 |
2.66 |
| KLA/ATP | 2.23 |
2.53 |
2.82 |
2.91 |
2.89 |
2.60 |
3.92 |
|
H2-M10.3
|  |
AY211080 |
major histocompatibility complex class Ib M10.3 mRNA, complete cds [AY211080] |
KLA | .95 |
1.08 |
.99 |
.95 |
1.00 |
1.11 |
1.04 |
| ATP | .98 |
.96 |
1.00 |
.99 |
1.00 |
.99 |
1.00 |
| KLA/ATP | 1.00 |
.99 |
1.00 |
1.00 |
.99 |
.96 |
1.03 |
|
H2-M10.4
|  |
NM_177634 |
histocompatibility 2, M region locus 10.4 (H2-M10.4), mRNA [NM_177634] |
KLA | 1.03 |
1.04 |
1.08 |
1.08 |
1.04 |
1.03 |
1.03 |
| ATP | 1.07 |
1.05 |
.97 |
1.08 |
.95 |
.97 |
1.02 |
| KLA/ATP | 1.02 |
.97 |
1.02 |
.99 |
.93 |
1.06 |
1.04 |
|
H2-M10.5
|  |
NM_177637 |
histocompatibility 2, M region locus 10.5 (H2-M10.5), mRNA [NM_177637] |
KLA | 1.00 |
1.04 |
1.13 |
.93 |
.99 |
1.00 |
1.07 |
| ATP | 1.02 |
1.02 |
1.04 |
.90 |
1.03 |
.99 |
.99 |
| KLA/ATP | 1.06 |
1.03 |
.97 |
1.03 |
1.03 |
.98 |
1.04 |
|
H2-M10.6
|  |
NM_201611 |
histocompatibility 2, M region locus 10.6 (H2-M10.6), mRNA [NM_201611] |
KLA | 1.06 |
.99 |
1.04 |
1.06 |
.98 |
1.03 |
.92 |
| ATP | 1.04 |
1.09 |
.96 |
.98 |
.94 |
1.07 |
.98 |
| KLA/ATP | 1.01 |
1.06 |
1.02 |
.96 |
.96 |
1.04 |
1.05 |
|
H2-M11 |  |
NM_177635 |
histocompatibility 2, M region locus 11 (H2-M11), mRNA [NM_177635] |
KLA | 1.03 |
1.07 |
1.06 |
1.02 |
.96 |
1.05 |
1.03 |
| ATP | 1.02 |
.96 |
1.08 |
.98 |
1.04 |
.94 |
.98 |
| KLA/ATP | 1.03 |
1.03 |
.99 |
1.01 |
1.01 |
.98 |
.99 |
|
H2-M3 |  |
NM_013819 |
histocompatibility 2, M region locus 3 (H2-M3), mRNA [NM_013819] |
KLA | 1.90 |
2.04 |
2.09 |
2.37 |
2.30 |
2.56 |
2.73 |
| ATP | 1.00 |
1.00 |
1.19 |
1.34 |
1.00 |
.70 |
1.09 |
| KLA/ATP | 1.77 |
1.94 |
2.37 |
2.49 |
1.89 |
1.67 |
2.06 |
|
H2-M9 |  |
NM_008205 |
histocompatibility 2, M region locus 9 (H2-M9), mRNA [NM_008205] |
KLA | 1.03 |
.99 |
.96 |
.98 |
1.01 |
.99 |
1.03 |
| ATP | .96 |
1.06 |
.94 |
.96 |
1.05 |
1.06 |
1.00 |
| KLA/ATP | .96 |
1.01 |
1.01 |
.99 |
.97 |
.95 |
.98 |
|
H2-Oa |  |
NM_008206 |
histocompatibility 2, O region alpha locus (H2-Oa), mRNA [NM_008206] |
KLA | 1.22 |
1.32 |
1.37 |
1.33 |
1.31 |
1.26 |
1.53 |
| ATP | 1.02 |
1.05 |
1.16 |
1.21 |
1.12 |
1.07 |
1.16 |
| KLA/ATP | 1.32 |
1.34 |
1.31 |
1.34 |
1.25 |
1.35 |
2.78 |
|
H2-Ob |  |
NM_010389 |
histocompatibility 2, O region beta locus (H2-Ob), mRNA [NM_010389] |
KLA | 1.05 |
1.07 |
1.01 |
.96 |
1.10 |
1.02 |
1.00 |
| ATP | 1.04 |
.99 |
1.00 |
1.03 |
.94 |
1.07 |
.94 |
| KLA/ATP | 1.02 |
.97 |
1.06 |
1.08 |
1.00 |
.96 |
1.05 |
|
H2-Q1 |  |
NM_010390 |
histocompatibility 2, Q region locus 1 (H2-Q1), mRNA [NM_010390] |
KLA | 1.05 |
1.08 |
1.03 |
1.02 |
.98 |
1.09 |
1.00 |
| ATP | .99 |
.92 |
.93 |
1.01 |
1.01 |
1.04 |
1.00 |
| KLA/ATP | 1.07 |
1.00 |
1.00 |
.91 |
.97 |
1.07 |
1.04 |
|
H2-Q10 |  |
NM_010391 |
histocompatibility 2, Q region locus 10 (H2-Q10), mRNA [NM_010391] |
KLA | 1.50 |
1.50 |
1.70 |
1.64 |
1.67 |
1.79 |
2.18 |
| ATP | 1.12 |
1.11 |
1.09 |
1.46 |
1.42 |
1.43 |
1.69 |
| KLA/ATP | 1.61 |
1.72 |
1.79 |
1.94 |
1.81 |
1.81 |
2.93 |
|
H2-Q2 |  |
NM_010392 |
histocompatibility 2, Q region locus 2 (H2-Q2), mRNA [NM_010392] |
KLA | 1.55 |
1.52 |
1.61 |
1.45 |
1.83 |
1.94 |
2.47 |
| ATP | 1.09 |
1.13 |
.92 |
1.16 |
1.17 |
1.30 |
1.88 |
| KLA/ATP | 1.55 |
1.70 |
1.58 |
1.80 |
1.64 |
1.87 |
3.43 |
|
H2-Q7 |  |
NM_010394 |
histocompatibility 2, Q region locus 7 (H2-Q7), mRNA [NM_010394] |
KLA | 1.57 |
1.58 |
1.74 |
1.55 |
1.82 |
2.00 |
2.76 |
| ATP | 1.05 |
1.09 |
.84 |
1.12 |
1.12 |
1.23 |
2.00 |
| KLA/ATP | 1.63 |
1.75 |
1.43 |
1.67 |
1.53 |
1.80 |
3.48 |
|
H2-Q8 |  |
NM_023124 |
histocompatibility 2, Q region locus 8 (H2-Q8), mRNA [NM_023124] |
KLA | 7.48 |
6.46 |
6.41 |
7.15 |
7.46 |
9.60 |
18.27 |
| ATP | 1.01 |
.98 |
1.48 |
2.05 |
1.93 |
3.83 |
8.26 |
| KLA/ATP | 6.72 |
7.10 |
9.11 |
10.95 |
10.71 |
12.88 |
31.43 |
|
H2-T22 |  |
NM_010397 |
histocompatibility 2, T region locus 22 (H2-T22), mRNA [NM_010397] |
KLA | 5.21 |
5.40 |
5.81 |
6.31 |
7.42 |
9.49 |
7.50 |
| ATP | 1.01 |
.95 |
.88 |
.92 |
.93 |
3.65 |
5.53 |
| KLA/ATP | 4.83 |
5.12 |
4.58 |
4.74 |
4.81 |
6.89 |
14.89 |
|
H2-T23 |  |
NM_010398 |
histocompatibility 2, T region locus 23 (H2-T23), mRNA [NM_010398] |
KLA | 1.83 |
1.80 |
1.92 |
1.86 |
2.32 |
2.56 |
3.43 |
| ATP | 1.03 |
1.08 |
.85 |
1.18 |
1.09 |
1.30 |
2.49 |
| KLA/ATP | 1.76 |
1.92 |
1.62 |
1.93 |
1.76 |
2.13 |
4.06 |
|
H2-T24 |  |
NM_008207 |
histocompatibility 2, T region locus 24 (H2-T24), mRNA [NM_008207] |
KLA | 3.02 |
3.26 |
4.14 |
4.26 |
5.15 |
6.06 |
5.89 |
| ATP | 1.08 |
1.09 |
1.32 |
1.35 |
1.17 |
1.71 |
6.71 |
| KLA/ATP | 3.23 |
3.31 |
3.54 |
3.85 |
3.07 |
3.73 |
9.10 |
|
H2-T3 |  |
NM_008208 |
histocompatibility 2, T region locus 3 (H2-T3), mRNA [NM_008208] |
KLA | .95 |
1.04 |
1.00 |
.97 |
.97 |
.99 |
1.00 |
| ATP | .98 |
1.08 |
1.03 |
1.01 |
.98 |
1.02 |
1.03 |
| KLA/ATP | 1.05 |
.96 |
1.02 |
1.04 |
1.05 |
1.00 |
.97 |
|
Icam1 |  |
BC008626 |
intercellular adhesion molecule, mRNA (cDNA clone MGC:6195 IMAGE:3588949), complete cds [BC008626] |
KLA | 36.67 |
32.93 |
28.63 |
27.91 |
14.65 |
8.16 |
4.15 |
| ATP | .96 |
.88 |
1.50 |
3.88 |
4.98 |
3.90 |
1.01 |
| KLA/ATP | 32.58 |
31.60 |
42.74 |
32.60 |
26.00 |
13.02 |
6.01 |
|
Icam1 |  |
NM_010493 |
intercellular adhesion molecule 1 (Icam1), mRNA [NM_010493] |
KLA | 15.66 |
15.20 |
12.96 |
12.31 |
9.39 |
6.17 |
3.81 |
| ATP | .96 |
1.06 |
1.21 |
4.19 |
4.33 |
3.16 |
1.06 |
| KLA/ATP | 14.31 |
15.46 |
17.84 |
17.60 |
13.77 |
8.36 |
5.42 |
|
Igh-VJ55 8 |  |
AY547436 |
immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] |
KLA | 1.06 |
1.05 |
1.01 |
.93 |
1.03 |
.96 |
.93 |
| ATP | .99 |
1.00 |
1.06 |
.95 |
.96 |
1.06 |
1.05 |
| KLA/ATP | .98 |
.94 |
1.07 |
.95 |
.97 |
.99 |
1.02 |
|
Igh-VJ55 8 |  |
CA578712 |
gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] |
KLA | .99 |
.94 |
1.01 |
1.10 |
.93 |
.97 |
.92 |
| ATP | .93 |
1.04 |
1.01 |
.98 |
1.05 |
.96 |
.95 |
| KLA/ATP | .99 |
.95 |
.95 |
.98 |
1.02 |
.98 |
.95 |
|
Igh-VJ55 8 |  |
ENSMUST00000103412 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] |
KLA | 1.01 |
.97 |
1.20 |
1.01 |
.98 |
1.44 |
1.24 |
| ATP | .99 |
.98 |
1.07 |
1.03 |
1.00 |
1.01 |
1.21 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.03 |
.97 |
1.13 |
1.30 |
|
Igh-VJ55 8 |  |
ENSMUST00000103413 |
ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] |
KLA | 1.00 |
.99 |
1.06 |
1.06 |
.99 |
1.03 |
1.02 |
| ATP | 1.08 |
1.06 |
1.06 |
1.06 |
1.02 |
1.06 |
.95 |
| KLA/ATP | 1.00 |
1.04 |
1.09 |
1.02 |
1.06 |
1.02 |
.95 |
|
Igh-VJ55 8 |  |
U39781 |
J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] |
KLA | .93 |
.89 |
.98 |
.97 |
1.03 |
1.00 |
.94 |
| ATP | 1.04 |
1.02 |
1.08 |
.94 |
.93 |
.90 |
.79 |
| KLA/ATP | .88 |
.89 |
.97 |
.93 |
.88 |
.92 |
.82 |
|
Itgal |  |
AK156251 |
activated spleen cDNA, RIKEN full-length enriched library, clone:F830013L17 product:integrin alpha L, full insert sequence [AK156251] |
KLA | 5.36 |
5.78 |
4.86 |
5.55 |
7.02 |
8.63 |
11.12 |
| ATP | .99 |
1.17 |
1.22 |
1.57 |
1.35 |
1.95 |
3.79 |
| KLA/ATP | 5.42 |
5.89 |
4.95 |
5.91 |
3.96 |
4.93 |
10.15 |
|
Itgal |  |
NM_008400 |
integrin alpha L (Itgal), mRNA [NM_008400] |
KLA | 4.48 |
5.17 |
5.28 |
5.82 |
7.82 |
8.09 |
16.96 |
| ATP | 1.03 |
1.06 |
1.24 |
1.44 |
1.34 |
2.02 |
4.59 |
| KLA/ATP | 4.71 |
5.63 |
5.49 |
5.60 |
3.66 |
4.65 |
17.76 |
|
Itgb2 |  |
NM_008404 |
integrin beta 2 (Itgb2), mRNA [NM_008404] |
KLA | .78 |
.78 |
.97 |
.74 |
1.04 |
.94 |
1.14 |
| ATP | 1.24 |
1.23 |
.79 |
.95 |
1.12 |
.84 |
1.10 |
| KLA/ATP | .99 |
1.01 |
.60 |
.83 |
.78 |
.73 |
.99 |
|
Itgb2l |  |
NM_008405 |
integrin beta 2-like (Itgb2l), mRNA [NM_008405] |
KLA | .87 |
.98 |
.98 |
1.00 |
1.05 |
1.07 |
1.10 |
| ATP | 1.24 |
1.23 |
1.13 |
1.14 |
1.29 |
1.05 |
1.05 |
| KLA/ATP | 1.02 |
1.08 |
1.08 |
1.06 |
.98 |
.93 |
.95 |
|
LOC67670 8 |  |
XM_992322 |
ref|PREDICTED: Mus musculus similar to class I (Qa) Q2k antigen (LOC676708), mRNA [XM_992322] |
KLA | 2.18 |
2.22 |
2.32 |
2.27 |
2.28 |
2.77 |
3.62 |
| ATP | 1.04 |
1.17 |
1.17 |
2.19 |
1.83 |
1.75 |
2.30 |
| KLA/ATP | 2.20 |
2.44 |
2.25 |
3.41 |
2.30 |
2.63 |
5.00 |
|
Lama2 |  |
AK046114 |
adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230342M05 product:laminin, alpha 2, full insert sequence. [AK046114] |
KLA | 1.06 |
1.00 |
.95 |
1.10 |
1.04 |
.99 |
.96 |
| ATP | .98 |
1.09 |
1.00 |
.97 |
.96 |
1.12 |
1.01 |
| KLA/ATP | .94 |
1.04 |
1.05 |
1.00 |
.99 |
1.00 |
.98 |
|
Lama2 |  |
NM_008481 |
laminin, alpha 2 (Lama2), mRNA [NM_008481] |
KLA | .96 |
.99 |
.96 |
1.02 |
.95 |
1.00 |
.97 |
| ATP | 1.05 |
1.00 |
1.01 |
.94 |
1.01 |
1.04 |
.96 |
| KLA/ATP | .99 |
1.04 |
1.06 |
1.10 |
.98 |
.95 |
.97 |
|
Lama2 |  |
U12147 |
laminin-2 alpha2 chain mRNA, complete cds. [U12147] |
KLA | .96 |
1.00 |
.99 |
1.00 |
.98 |
1.02 |
1.03 |
| ATP | 1.01 |
.99 |
1.02 |
1.04 |
1.01 |
.99 |
1.02 |
| KLA/ATP | 1.00 |
1.01 |
1.00 |
1.01 |
.99 |
1.04 |
1.00 |
|
Mm.19506 1 |  |
76253707 |
Unknown |
KLA | 5.35 |
4.83 |
5.36 |
6.20 |
6.87 |
9.80 |
7.83 |
| ATP | .97 |
.90 |
.96 |
.77 |
.80 |
3.98 |
5.87 |
| KLA/ATP | 4.63 |
4.51 |
4.51 |
3.75 |
4.39 |
7.21 |
16.38 |
|
Mm.25070 5 |  |
7305294 |
Unknown |
KLA | 1.01 |
1.06 |
1.00 |
1.05 |
.99 |
1.07 |
.99 |
| ATP | 1.00 |
1.05 |
1.06 |
1.03 |
.89 |
1.01 |
1.10 |
| KLA/ATP | 1.04 |
.92 |
1.05 |
1.07 |
1.00 |
1.00 |
1.05 |
|
Mm.25500 3 |  |
161484596 |
Unknown |
KLA | .35 |
.34 |
.35 |
.34 |
.22 |
.19 |
.10 |
| ATP | 1.09 |
1.27 |
1.13 |
1.29 |
2.25 |
1.66 |
2.22 |
| KLA/ATP | .38 |
.36 |
.39 |
.40 |
.49 |
.42 |
.32 |
|
Mm.27304 9 |  |
119672895 |
Unknown |
KLA | .23 |
.22 |
.22 |
.22 |
.30 |
.51 |
.16 |
| ATP | 1.08 |
1.05 |
.88 |
.78 |
.47 |
.09 |
.20 |
| KLA/ATP | .28 |
.22 |
.21 |
.24 |
.26 |
.22 |
.12 |
|
Mm.43967 5 |  |
133778954 |
Unknown |
KLA | 1.76 |
1.74 |
1.70 |
1.72 |
1.75 |
2.14 |
3.19 |
| ATP | 1.00 |
1.01 |
1.18 |
1.28 |
1.25 |
1.48 |
1.84 |
| KLA/ATP | 1.67 |
1.64 |
1.70 |
1.79 |
1.63 |
2.04 |
3.36 |
|
Mm.43967 5 |  |
149275074 |
Unknown |
KLA | 2.17 |
2.23 |
2.26 |
2.58 |
2.26 |
2.10 |
1.43 |
| ATP | .96 |
.91 |
1.12 |
.90 |
.70 |
1.10 |
1.47 |
| KLA/ATP | 1.96 |
2.10 |
1.92 |
1.51 |
1.12 |
1.35 |
1.99 |
|
Mm.44165 1 |  |
160333403 |
Unknown |
KLA | 5.45 |
5.27 |
5.02 |
6.34 |
6.63 |
10.05 |
8.10 |
| ATP | .91 |
.84 |
.96 |
.75 |
.78 |
3.91 |
6.03 |
| KLA/ATP | 4.29 |
4.38 |
4.50 |
3.55 |
4.22 |
7.22 |
17.63 |
|
Mm.45798 3 |  |
118131045 |
Unknown |
KLA | .95 |
1.08 |
1.17 |
1.13 |
1.10 |
1.13 |
1.06 |
| ATP | 1.02 |
.97 |
1.03 |
1.07 |
1.17 |
1.22 |
1.05 |
| KLA/ATP | 1.04 |
1.05 |
1.06 |
1.11 |
1.41 |
1.49 |
1.08 |
|
Myh1 |  |
AK009974 |
adult male tongue cDNA, RIKEN full-length enriched library, clone:2310058C22 product:myosin, heavy polypeptide 1, skeletal muscle, adult, full insert sequence [AK009974] |
KLA | .98 |
.99 |
.95 |
1.03 |
.98 |
.98 |
.98 |
| ATP | .98 |
1.00 |
1.02 |
1.00 |
.99 |
1.01 |
.99 |
| KLA/ATP | .98 |
.95 |
1.05 |
1.06 |
1.01 |
1.00 |
1.06 |
|
Myh1 |  |
NM_030679 |
myosin, heavy polypeptide 1, skeletal muscle, adult (Myh1), mRNA [NM_030679] |
KLA | 1.04 |
.99 |
.98 |
1.04 |
1.04 |
1.00 |
1.05 |
| ATP | .95 |
1.02 |
1.09 |
1.02 |
.98 |
1.03 |
1.06 |
| KLA/ATP | 1.02 |
.98 |
1.05 |
1.01 |
.96 |
1.00 |
.99 |
|
Myh10 |  |
NM_175260 |
myosin, heavy polypeptide 10, non-muscle (Myh10), mRNA [NM_175260] |
KLA | 1.04 |
1.08 |
1.24 |
1.13 |
1.13 |
1.02 |
.77 |
| ATP | 1.06 |
1.09 |
1.04 |
1.04 |
.94 |
.84 |
.79 |
| KLA/ATP | 1.09 |
1.16 |
1.08 |
1.05 |
1.05 |
.88 |
.75 |
|
Myh11 |  |
NM_013607 |
myosin, heavy polypeptide 11, smooth muscle (Myh11), mRNA [NM_013607] |
KLA | 1.01 |
1.05 |
1.02 |
1.06 |
1.00 |
.96 |
1.01 |
| ATP | 1.09 |
.98 |
1.00 |
1.00 |
1.03 |
.97 |
1.13 |
| KLA/ATP | .99 |
1.06 |
1.05 |
1.03 |
.98 |
1.05 |
1.10 |
|
Myh13 |  |
NM_001081250 |
myosin, heavy polypeptide 13, skeletal muscle (Myh13), mRNA [NM_001081250] |
KLA | 1.01 |
1.04 |
1.01 |
.99 |
1.00 |
1.06 |
.97 |
| ATP | .99 |
1.02 |
1.05 |
1.08 |
.99 |
.98 |
1.01 |
| KLA/ATP | 1.01 |
.98 |
.99 |
1.02 |
1.06 |
1.00 |
1.01 |
|
Myh14 |  |
NM_028021 |
myosin, heavy polypeptide 14 (Myh14), mRNA [NM_028021] |
KLA | 1.10 |
1.12 |
1.05 |
1.07 |
1.10 |
1.06 |
1.07 |
| ATP | 1.02 |
1.04 |
1.03 |
1.02 |
1.01 |
1.04 |
1.10 |
| KLA/ATP | 1.02 |
1.07 |
1.06 |
1.04 |
1.13 |
1.10 |
1.13 |
|
Myh2 |  |
AK036437 |
adult male bone cDNA, RIKEN full-length enriched library, clone:9830108D13 product:SIMILAR TO MYOSIN, HEAVY POLYPEPTIDE 2, SKELETAL MUSCLE, ADULT homolog [Mus musculus], full insert sequence. [AK036437] |
KLA | .97 |
1.04 |
1.02 |
1.02 |
.95 |
1.02 |
.95 |
| ATP | 1.00 |
.98 |
1.05 |
1.00 |
.95 |
1.08 |
.97 |
| KLA/ATP | .95 |
1.00 |
.94 |
.99 |
.95 |
.98 |
.99 |
|
Myh2 |  |
NM_001039545 |
myosin, heavy polypeptide 2, skeletal muscle, adult (Myh2), mRNA [NM_001039545] |
KLA | .99 |
.98 |
1.03 |
1.02 |
.98 |
.98 |
1.01 |
| ATP | 1.01 |
.98 |
.98 |
1.01 |
.97 |
.99 |
.95 |
| KLA/ATP | .95 |
1.00 |
1.05 |
1.00 |
.96 |
.99 |
1.02 |
|
Myh3 |  |
NM_001099635 |
myosin, heavy polypeptide 3, skeletal muscle, embryonic (Myh3), mRNA [NM_001099635] |
KLA | 1.01 |
.97 |
.95 |
1.07 |
1.08 |
1.08 |
1.07 |
| ATP | 1.02 |
.97 |
.98 |
1.02 |
.94 |
.96 |
1.09 |
| KLA/ATP | 1.03 |
1.05 |
1.03 |
1.17 |
1.73 |
2.01 |
1.22 |
|
Myh4 |  |
NM_010855 |
myosin, heavy polypeptide 4, skeletal muscle (Myh4), mRNA [NM_010855] |
KLA | 1.06 |
1.00 |
1.00 |
1.02 |
1.06 |
1.06 |
1.01 |
| ATP | .99 |
1.04 |
1.02 |
.98 |
.96 |
1.02 |
1.06 |
| KLA/ATP | 1.01 |
1.00 |
1.00 |
1.04 |
.99 |
1.00 |
1.03 |
|
Myh6 |  |
NM_010856 |
myosin, heavy polypeptide 6, cardiac muscle, alpha (Myh6), mRNA [NM_010856] |
KLA | 1.00 |
1.01 |
1.00 |
.99 |
1.00 |
.98 |
1.02 |
| ATP | 1.00 |
.99 |
.96 |
.98 |
1.01 |
1.01 |
.98 |
| KLA/ATP | 1.03 |
1.04 |
1.01 |
1.01 |
.99 |
1.00 |
1.02 |
|
Myh7 |  |
NM_080728 |
myosin, heavy polypeptide 7, cardiac muscle, beta (Myh7), mRNA [NM_080728] |
KLA | 1.06 |
1.13 |
1.14 |
1.07 |
1.09 |
1.06 |
1.03 |
| ATP | .96 |
1.01 |
1.09 |
1.05 |
1.15 |
1.16 |
1.12 |
| KLA/ATP | 1.01 |
1.05 |
1.02 |
.98 |
1.29 |
1.62 |
1.09 |
|
Myh8 |  |
NM_177369 |
myosin, heavy polypeptide 8, skeletal muscle, perinatal (Myh8), mRNA [NM_177369] |
KLA | 1.03 |
.98 |
1.04 |
.99 |
1.02 |
.99 |
.97 |
| ATP | 1.06 |
1.07 |
.97 |
.99 |
.98 |
.98 |
1.01 |
| KLA/ATP | 1.11 |
1.11 |
1.05 |
1.03 |
.98 |
1.07 |
.95 |
|
Myh9 |  |
NM_022410 |
myosin, heavy polypeptide 9, non-muscle (Myh9), transcript variant 1, mRNA [NM_022410] |
KLA | .69 |
.65 |
.55 |
.57 |
.70 |
1.14 |
.82 |
| ATP | .91 |
.98 |
1.08 |
.80 |
.77 |
.99 |
.84 |
| KLA/ATP | .62 |
.66 |
.69 |
.49 |
.47 |
.54 |
.70 |
|
Prf1 |  |
NM_011073 |
perforin 1 (pore forming protein) (Prf1), mRNA [NM_011073] |
KLA | .99 |
1.02 |
1.05 |
1.08 |
1.00 |
1.03 |
.98 |
| ATP | 1.00 |
.97 |
1.03 |
.97 |
.97 |
.98 |
.91 |
| KLA/ATP | 1.07 |
.99 |
.93 |
.98 |
.98 |
.95 |
.99 |
|
Rac1 |  |
NM_009007 |
RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] |
KLA | 1.02 |
1.01 |
1.02 |
.99 |
1.03 |
1.15 |
1.08 |
| ATP | .99 |
1.15 |
1.01 |
1.27 |
1.06 |
1.20 |
1.06 |
| KLA/ATP | 1.00 |
1.04 |
.88 |
1.16 |
.91 |
1.21 |
1.38 |
|
Rac2 |  |
NM_009008 |
RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] |
KLA | 1.55 |
1.68 |
1.86 |
2.15 |
3.36 |
3.59 |
3.74 |
| ATP | 1.13 |
1.16 |
.74 |
.99 |
.84 |
.91 |
1.66 |
| KLA/ATP | 1.59 |
1.71 |
1.19 |
1.56 |
1.21 |
1.60 |
3.48 |
|
Rac3 |  |
NM_133223 |
RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] |
KLA | 2.03 |
2.20 |
2.64 |
2.18 |
2.95 |
2.29 |
1.41 |
| ATP | 1.02 |
1.12 |
.94 |
1.42 |
1.16 |
.84 |
.87 |
| KLA/ATP | 2.30 |
2.32 |
1.57 |
2.55 |
1.75 |
1.47 |
1.61 |
|
Sgca |  |
NM_009161 |
sarcoglycan, alpha (dystrophin-associated glycoprotein) (Sgca), mRNA [NM_009161] |
KLA | .96 |
1.06 |
1.08 |
1.01 |
1.06 |
1.10 |
1.08 |
| ATP | 1.00 |
.99 |
1.04 |
1.04 |
1.06 |
.90 |
1.05 |
| KLA/ATP | .98 |
.96 |
1.06 |
1.03 |
1.18 |
1.17 |
1.11 |
|
Sgcb |  |
AK009080 |
adult male tongue cDNA, RIKEN full-length enriched library, clone:2310001O14 product:unclassifiable, full insert sequence. [AK009080] |
KLA | 1.32 |
1.24 |
1.20 |
1.23 |
1.10 |
1.06 |
.97 |
| ATP | .93 |
.85 |
.88 |
.89 |
.94 |
.93 |
1.01 |
| KLA/ATP | 1.19 |
1.13 |
.98 |
.92 |
1.03 |
1.04 |
.97 |
|
Sgcb |  |
NM_011890 |
sarcoglycan, beta (dystrophin-associated glycoprotein) (Sgcb), mRNA [NM_011890] |
KLA | 2.98 |
2.85 |
3.65 |
3.67 |
3.43 |
2.59 |
1.47 |
| ATP | 1.15 |
1.07 |
1.28 |
1.20 |
1.19 |
1.03 |
1.42 |
| KLA/ATP | 2.87 |
3.08 |
3.92 |
3.05 |
2.71 |
2.38 |
1.91 |
|
Sgcd |  |
NM_011891 |
sarcoglycan, delta (dystrophin-associated glycoprotein) (Sgcd), mRNA [NM_011891] |
KLA | 1.08 |
1.07 |
1.01 |
1.01 |
1.07 |
.96 |
.93 |
| ATP | 1.00 |
.95 |
1.03 |
1.08 |
1.00 |
.98 |
1.01 |
| KLA/ATP | .97 |
.97 |
1.08 |
1.03 |
.95 |
1.01 |
1.03 |
|
Sgcg |  |
NM_011892 |
sarcoglycan, gamma (dystrophin-associated glycoprotein) (Sgcg), mRNA [NM_011892] |
KLA | .94 |
.94 |
1.05 |
1.06 |
1.00 |
1.02 |
.98 |
| ATP | 1.02 |
.98 |
1.19 |
1.08 |
1.10 |
1.14 |
.90 |
| KLA/ATP | 1.02 |
1.06 |
1.09 |
1.22 |
1.13 |
1.08 |
.82 |
|